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tion receptors such as CD14, Toll-like receptor 4 (TLR4) and 
mannose receptor, and this correlated with an increase in 
proinflammatory cytokine production after stimulation 
with the TLR4 ligand lipopolysaccharide. The heterolo-
gous production of Th1 (IFN-γ) and Th17 (IL-17 and IL-22) 
immune responses to nonmycobacterial stimulation re-
mained strongly elevated even 1 year after BCG vaccination. 
In conclusion, BCG induces sustained changes in the im-
mune system associated with a nonspecific response to in-
fections both at the level of innate trained immunity and at 
the level of heterologous Th1/Th17 responses. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 Nonspecific beneficial effects of BCG (Bacillus 
Calmette-Guérin) have been described for many decades. 
Soon after its introduction in the 1920s, epidemiological 
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 Abstract 
 We have recently shown that BCG (Bacillus Calmette-Guérin) 
vaccination in healthy volunteers induces epigenetic repro-
gramming of monocytes, leading to increased cytokine pro-
duction in response to nonrelated pathogens for up to 
3 months after vaccination. This phenomenon was named 
‘trained immunity’. In the present study we assessed wheth-
er BCG was able to induce long-lasting effects on both 
trained immunity and heterologous T helper 1 (Th1) and 
Th17 immune responses 1 year after vaccination. The pro-
duction of TNFα and IL-1β to mycobacteria or unrelated 
pathogens was higher after 2 weeks and 3 months postvac-
cination, but these effects were less pronounced 1 year after 
vaccination. However, monocytes recovered 1 year after 
vaccination had an increased expression of pattern recogni-
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studies surprisingly demonstrated that BCG protects 
against infant mortality independent of its effect on tu-
berculosis (TB)  [1–5] . Recent studies supported these 
findings and suggested a reduction of the burden of infec-
tions other than TB  [6–10] . For example, BCG decreased 
by half the neonatal mortality of children in several recent 
trials in West Africa  [8, 9, 11–14] , while in a case-control 
study in Brazil, BCG reduced the risk of death from pneu-
monia by 50% in children less than 1 year of age  [7] . In 
light of these data, the question arises as to which mecha-
nisms mediate these nonspecific immune effects of BCG, 
and how long do they last? 
 Two possible immunological mechanisms have been 
proposed to explain the nonspecific beneficial effects of 
vaccination. The first such mechanism is heterologous 
immunity, in which cross-protection is mediated by het-
erologous T cell memory responses  [15] . However, heter-
ologous immunity needs at least a couple of weeks to de-
velop, and it is thus highly unlikely to be responsible for 
the very rapid effects observed on perinatal immunity 
 [14] . A second mechanism of protection has been recent-
ly proposed in the form of epigenetic reprogramming of 
immune cells, a phenomenon conferring nonspecific im-
mune memory to innate immune responses and termed 
‘trained immunity’  [16] . Many species of organisms lack-
ing adaptive immunity, such as plants  [17] or insects  [18, 
19] , manifest robust immune memory after previous ex-
posure to infections or certain microbial components, 
and adaptive features of innate immunity have also been 
demonstrated in mice devoid of functional adaptive im-
mune responses  [20, 21] . Prominent microbial compo-
nents that are able to potentiate the effector function of 
innate immune cells and protect against infections are 
mycobacterial stimuli such as BCG, complete Freund’s 
adjuvant and muramyl dipeptide  [22–25] . Recently, we 
have shown that BCG vaccination in healthy volunteers 
led to NOD2-dependent epigenetic reprogramming of 
monocytes, which resulted in an increased expression of 
cellular receptors on the monocytes, accompanied by 
higher cytokine production in response to nonrelated 
pathogens  [26] . This newly described mechanism might 
represent the explanation for the rapid nonspecific pro-
tective effects induced by BCG vaccination. However, it 
is not known how long trained immunity and/or heter-
ologous immunity persist after BCG vaccination. There-
fore, in the present study we investigated the long-term 
nonspecific effects of BCG vaccination in healthy volun-
teers by assessing the responses of both innate and adap-
tive immune cells to nonmycobacterial stimulation in a 
period extending up until 1 year after the vaccination. 
 Materials and Methods 
 Subjects 
 Individuals (age range 20–36 years) scheduled to receive a BCG 
vaccination at the public health service because of travel to or work 
in TB-endemic countries were asked to participate in this trial. 
Twenty healthy individuals were included between August and 
November 2010. Blood was drawn before, and 2 weeks, 3 months 
and 1 year after the BCG vaccination. Two participants were lost 
to follow-up after 3 months. The study was approved by the Arn-
hem-Nijmegen Ethical Committee. 
 PBMC Stimulation Assays 
 For the PBMC stimulation assays the mononuclear cell fraction 
was isolated by density centrifugation from blood diluted 1: 1 in 
pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, Uppsa-
la, Sweden). Cells were washed twice in saline and resuspended in 
culture medium (RPMI, Invitrogen, Carlsbad., Calif., USA) sup-
plemented with gentamicin 10 μg/ml,  L -glutamine 10 m M and py-
ruvate 10 m M . Cells were counted in a Coulter counter (Coulter 
Electronics) and the number was adjusted to 5 × 10 6 cells/ml. A 
total of 5 × 10 5 mononuclear cells in a 100-μl volume was added to 
round-bottomed 96-well plates (Greiner) with RPMI or with son-
icated  Mycobacterium tuberculosis  (MTB) H37Rv (1 μg/ml end 
protein concentration), heat-killed  Candida  albicans (1 × 10 6 mi-
croorganisms/ml, strain UC820),  Staphylococcus aureus (1 × 10 6 
microorganisms/ml, clinical isolate) or  Escherichia coli lipopoly-
saccharide (LPS; 1 ng/ml; Sigma-Aldrich, St. Louis, Mo., USA). 
After 24, 48 h or 7 days supernatants were stored at –20  °  C. Cyto-
kine concentrations were assessed in the supernatants using en-
zyme-linked immunosorbent assay (ELISA). 
 Cytokine Measurements 
 Circulating IFN-γ, IL-17 and IL-22 were measured in plasma 
with Sanquin Pelikine ELISA kits (IFN-γ) or R&D Quantikine 
ELISA kits (IL-17 and IL-22; R&D Systems, Minneapolis, Minn., 
USA), respectively, following the description of the manufacturer. 
Cytokine measurements of TNFα, IL-1β, IFN-γ, IL-17 and IL-22 
after PBMC stimulation were performed in the supernatants using 
commercial ELISA kits from R&D Systems (TNFα, IL-1β, IL-17 
and IL-22) or Sanquin (IFN-γ; Amsterdam, The Netherlands). In 
a small proportion of baseline samples in which cytokine concen-
trations were beyond the detection limit, these outliers were ex-
cluded from the analysis.
 FACS Analysis 
 Cells were phenotypically analyzed by ten-color and five-color 
flow cytometry using a Coulter Navios and Coulter Cytomics FC 
500, respectively (Beckman Coulter, Fullerton, Fla., USA) and 
evaluated using Kaluza 1.1 software (Beckman Coulter). In order 
to guarantee reliable results the flow cytometry was calibrated with 
flow set pro beads (Beckman Coulter). Cells were washed in PBS 
with 1% bovine serum albumin before being labeled with fluoro-
chrome-conjugated mAbs. After incubation for 30 min at 4   °   C in 
the dark, cells were washed twice to remove unbound antibodies 
and analyzed. For cell surface staining, the following mAbs were 
used: CD3-PECy7 (737657), CD4-PB (A82789), CD8-APC-A700 
(A66332), CD45-PO (A96416), CD11b-PE (IM25814), CD14-
ECD (IM2707U), CD45-PC7 (IM3548; all from Beckman Coulter 
Corporation), CD284-PE (TLR4; 312806) and CD206-PE (321106; 
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both form Biolegend), CD16-FITC (335035) and CD282-APC 
(TLR2; 558319; both from BD biosciences) and dectin-1-APC 
(FAB1859A; R&D Systems). 
 Statistical Analysis 
 Differences were analyzed using the Wilcoxon signed-rank test 
or Friedman test for paired samples. p < 0.05 was considered statis-
tically significant. Unless otherwise stated, data are shown as cumu-
lative results of data obtained in all volunteers (means + SEM).
 Results 
 The Effect of BCG Vaccination on Heterologous Th1 
and Th17 Responses 
 FACS analyses of T cell subpopulations did not show 
major shifts in CD4 and CD8 lymphocytes (online suppl. 
fig. 1; for all online suppl. material, see www.karger.com/
doi/10.1159/000355628). Circulating concentrations of 
the T cell-derived cytokines IFN-γ, IL-17 and IL-22 were 
below the detection limit at all time points (data not 
shown). In contrast, 2 weeks and 3 months after BCG vac-
cination, IFN-γ production induced by MTB was 7-fold 
higher than the production before vaccination, as also re-
ported previously  [26] . Interestingly, this effect remained 
present for at least 1 year ( fig. 1 a). A similar increase in 
cytokine production after 2 weeks and 3 months was ob-
served when cells were stimulated with unrelated patho-
gens ( C. albicans or  S. aureus ;  fig. 1 b,  c). The increased 
production persisted until 1 year after vaccination in the 
case of  S. aureus , while it largely retuned to prevaccina-
tion levels after  C. albicans  stimulation.
 In addition to its effects on Th1 responses, we sought 
to investigate the effect of BCG vaccination on the pro-
duction of Th17-derived cytokines, namely IL-17 and IL-
22. MTB-stimulated IL-17 production was significantly 
higher in cells retrieved after BCG vaccination ( fig. 2 a). 
Moreover, this effect was independent of the stimulating 
pathogen, as a persistently increased IL-17 production 
was also observed upon stimulation with  C. albicans 
( fig. 2 b) and  S. aureus ( fig. 2 c). The increased heterolo-
gous Th17 immunity was also reflected by the potentiated 
IL-22 production after BCG vaccination. This was appar-
ent after stimulation of cells with MTB,  C. albicans or  S. 
aureus  ( fig. 2 d–f).
 The Effect of BCG Vaccination on Trained Immunity 
 Previously, we reported that BCG affected production 
of proinflammatory cytokines produced by monocytes, a 
prototypic innate immune cell population  [26] . While 
TNFα and IL-1β production was higher 2 weeks and 
3 months after vaccination, it largely returned to normal 
1 year after BCG vaccination. This waning effect on TNFα 
and IL-1β release was observed upon stimulation of the 
cells with MTB, as well as with the nonrelated pathogen 
 C. albicans ( fig. 3 a, b) or  S. aureus  (not shown). Similar 
data were obtained on IL-1β production (data not shown). 
However, LPS-induced TNFα ( fig. 3 c) and IL-1β ( fig. 3 d) 
production 1 year after vaccination remained significant-
ly higher compared to prevaccination levels. 
 The Effect of BCG Vaccination on Receptor Expression 
on Monocytes 
 The expression of several pattern recognition recep-
tors and activation markers on monocytes showed a sus-
tained rise in expression over time.  Figure 4 presents 
mean fluorescent indexes (MFI) of either markers of ac-
tivity of monocytes (CD14 and CD11b;  fig. 4 a, b), Toll-
like receptor 4 (TLR4) and TLR2 ( fig. 4 c, d), and C-type 
lectins (mannose receptor, MR, and dectin-1;  fig. 4 e, f). 
The increase in MFI was receptor specific, as not all TLRs 
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 Fig. 1. BCG vaccination increased the heterologous Th1 respons-
es. PBMCs isolated from 18 volunteers before and after (2 weeks, 
3 months and 1 year) vaccination were stimulated in vitro with 
sonicated  MTB  ( a ), heat-killed  C. albicans yeast ( b ) and  S. aureus 
( c ). IFN-γ production was assessed in the supernatants by ELISA. 
 *  p < 0.05;  * *  p < 0.01. 
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or C-type lectins were influenced by the vaccination. The 
activity markers CD14 and CD11b showed persistent 
higher levels of expression on monocytes that lasted for at 
least 1 year. Also, TLR4 and MR expression on monocytes 
were increased after BCG vaccination 1 year after vaccina-
tion. No effect was seen on the expression of TLR2 or dec-
tin-1 ( fig. 4 d, f). Online supplementary figure 2 shows the 
gating strategy for monocytes used in  figure 4 . In addition, 
online supplementary figure 3 presents representative 
histograms of all the receptors shown in  figure 4 .
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 Fig. 2. BCG induces long-lasting heterologous Th17 responses. 
PBMCs isolated from 18 volunteers before and after (2 weeks, 
3 months and 1 year) vaccination were stimulated in vitro with 
sonicated  MTB  ( a ,  d ), heat-killed  C. albicans yeast ( b ,  e ) and  S. 
aureus ( c ,  f ). IL-17 ( a–c ) and IL-22 ( d–f ) production was assessed 
by ELISA in the supernatants.  *  p < 0.05;  * *  p < 0.01;  * * *  p < 0.005. 
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 Fig. 3. Effect of BCG on innate immune cy-
tokines. PBMCs isolated from 18 volun-
teers before and after (2 weeks, 3 months 
and 1 year) vaccination were stimulated in 
vitro with sonicated  MTB  ( a ), heat-killed 
 C. albicans yeast ( b ) and LPS ( c ,  d ). TNFα 
( a–c ) and IL-1β ( d ) production was as-
sessed by ELISA in the supernatants.  *  p < 
0.05;  * *  p < 0.01. 
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 Discussion  
 BCG has beneficial effects on infections other than TB, 
yet the immunological mechanisms responsible for these 
effects remain obscure. Recently, two immunological 
mechanisms have been suggested to mediate these effects: 
the short-time effects are most likely mediated by epigen-
etic reprogramming of innate immune cells, a process 
called ‘trained immunity’  [26] , while long-term effects 
may be mediated by heterologous Th1/Th17 immunity 
 [15] , possibly in combination with residual trained immu-
nity effects. In the present study we show that BCG vacci-
nation induces nonspecific potentiation effects of both in-
nate trained immunity and heterologous T helper respons-
es that are clearly present for at least 1 year after vaccination.
 The long-term effects after BCG vaccination are most 
prominent on heterologous Th1 and Th17 responses. An 
explanation for this could be the process of ‘cross-protec-
tion’ described 5 decades ago  [27] , or termed later as ‘het-
erologous immunity’  [15, 28] . The classical form of cross-
protection is mediated by lymphocytes that release IFN-γ 
after stimulation with a first-encountered pathogen and 
subsequently activate bystander macrophages, generat-
ing a state of temporary heightened innate immunity 
against a secondary infection, which wanes rapidly once 
the primary pathogen is eliminated  [29] . The second 
form is long-lived and therefore maybe more comparable 
with our findings: Berg et al.  [30] described that both ef-
fector and memory CD8+ cells have the potential to se-
crete IFN-γ in response to IL-12 and IL-18 in the absence 
of a related antigen. The IL-12 and IL-18 are produced in 
the initial stages of a secondary infection. One additional 
possible explanation can be epitope sharing as described 
previously, although this is unlikely to play a major role 
for explaining the increased responses to  C. albicans or  S. 
aureus  after BCG vaccination. 
 One could speculate that the increased reactivity of 
Th17 cells occurs in a similar fashion. The general prin-
ciple of the induction of Th17 responses is similar to that 
of Th1 immunity, with the difference that IL-1β and IL-23 
(rather than IL-12 and IL-18) are the cytokines respon-
sible for Th17 differentiation. The increased expression 
of pattern recognition receptors known to induce Th17 
responses such as MR  [31] , and proinflammatory cyto-
kines such as IL-1β  [32] , may at least partly account for 
the induction of heterologous Th17 immunity. The in-
crease in these typical innate immune responses during 
the induction of trained immunity could thus contribute 
to heterologous T helper responses, but this direct rela-
tionship remains to be formally demonstrated by future 
studies. In addition, one may also speculate regarding po-
tential deleterious effects of BCG-induced heterologous 
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 Fig. 4. BCG alters the phenotype of circulating monocytes in 
healthy volunteers. Average surface expression levels of activation 
markers CD14+ ( a ) and CD11b ( b ), TLR4 ( c ) and TLR2 ( d ), and 
C-type lectin receptors MR ( e ) and dectin-1 ( f ) within the CD14+ 
monocytes population isolated from 18 volunteers before and after 
BCG vaccination.  *  p < 0.05;  * *  p < 0.01;  * * *  p < 0.005. 
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immunity during autoimmune processes. An important 
difference between BCG vaccination and autoimmune 
disorders is that while autoimmunity induces spontane-
ous IL-17 production with autoimmune tissue damage, 
BCG vaccination only induces a primed status of the cells 
to respond more strongly to secondary microbial stimu-
lation. Without stimulation, no higher production of 
these cytokines was seen. In line with this, one study even 
reported a beneficial effect of BCG vaccination on type 1 
diabetes mellitus  [33] , and beneficial effects on asthma 
and allergies have also been reported  [34] .
 In addition to the effects on heterologous immunity, 
BCG vaccination also shows long-term effects on innate 
trained immunity. This is revealed by the persistent in-
crease in LPS-mediated proinflammatory cytokine pro-
duction, and expression of pattern recognition recep-
tors and monocyte activation markers. One may hypoth-
esize that these two effects are related, as it is mainly the 
expression of the LPS receptors TLR4 and CD14  [35] , 
which remained high 1 year after BCG, that are responsible 
for enhanced cytokine responses after LPS stimulation. In 
contrast, the expression of other pattern recognition recep-
tors such as dectin-1 and TLR2 was not affected by BCG 
vaccination. While alterations in  S. aureus and  C. albicans -
mediated cytokine production were clearly present 2 weeks 
and 3 months after vaccination, these effects waned after 
1 year. This suggests that at least for some innate immune 
pathways, the epigenetic reprogramming responsible for 
the trained immunity effects  [26] are relatively short lived 
and are present for months rather than years.
 In conclusion, in the present study we have charac-
terized the long-term nonspecific immunological ef-
fects  of BCG vaccination. We have previously shown 
that innate immunity has adaptive features, termed 
trained immunity  [16] . While a maximum duration of 
trained immunity effects of 3 months has been report-
ed to date  [26] , in the present study we have shown that 
the nonspecific training effects of BCG vaccination on 
receptor expression and LPS-induced proinflammato-
ry  cytokines is long-standing and present for at least 
1  year. In addition, strongly increased heterologous 
Th1 and Th17 responses have been observed 1 year after 
the vaccination. These double effects of BCG vaccina-
tion on both trained immunity and heterologous T cell 
responses provide a likely explanation for both the 
short- and long-term nonspecific effects of BCG, which 
have been known for decades and may have important 
implications for vaccine development and healthcare 
policy.
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